COCSF
COCA COLA FEMSA SAB DE CV
$11.04
+3.15%
No data for this timeframe.
Vol
SEC Reports3
Exchange OTC·Sector Bottled & Canned Soft Drinks & Carbonated Waters·CIK 0000910631·Prev Close $10.70
Recent Activity
Jun 1, 2026
SEC
Coca-Cola FEMSA filed its annual Report on the level of adherence to the Code of Best Corporate Practices for fiscal yea
6-K — Impact 2/10
Apr 29, 2026
SEC
Coca-Cola FEMSA reported Q1 2026 results with consolidated revenue up 1.1% to Ps. 70,925 million and volume up 1.2%, but
6-K — Impact 5/10
Apr 16, 2026
SEC
Coca-Cola FEMSA filed its 2025 annual report on Form 20-F with the SEC, making audited financial statements available to
6-K — Impact 3/10
Analyst Ratings
3Strong Buy
10Buy
4Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 20, 2015 | JP Morgan | MAINTAIN | Neutral |
| Jan 23, 2015 | JP Morgan | MAINTAIN | Neutral |
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 3.3/10.
NEUTRAL
6-K
2/10
Coca-Cola FEMSA filed its annual Report on the level of adherence to the Code of Best Corporate Prac
Jun 1, 2026
MIXED
6-K
5/10
Coca-Cola FEMSA reported Q1 2026 results with consolidated revenue up 1.1% to Ps. 70,925 million and
Apr 29, 2026
NEUTRAL
6-K
3/10
Coca-Cola FEMSA filed its 2025 annual report on Form 20-F with the SEC, making audited financial sta
Apr 16, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Apr 2015): 76% buy across 17 analysts — 3 strong buy, 10 buy, 4 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $4.4B | 13.4% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $4.4B | 13.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $17.7B | 4.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $19.1B | 7.8% | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 20, 2015 | JP Morgan | MAINTAIN | — | Neutral |
| Jan 23, 2015 | JP Morgan | MAINTAIN | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 10 | 4 | 0 | 0 | 76% | |
| May 1, 2026 | 3 | 11 | 4 | 0 | 0 | 78% | |
| Apr 1, 2026 | 3 | 11 | 4 | 0 | 0 | 78% | |
| Mar 1, 2026 | 3 | 12 | 3 | 0 | 0 | 83% | |
| Feb 1, 2026 | 3 | 12 | 3 | 0 | 0 | 83% | |
| Jan 1, 2026 | 3 | 13 | 2 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.